Siegfried Holding AG - Company Profile
Powered by 
All the sales intelligence you need on Siegfried Holding AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Siegfried Holding AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Siegfried Holding AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Siegfried Holding AG (Siegfried) is a contract development and manufacturing organization. The company focuses on the production of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company's services portfolio includes chemical development, analytical development, pilot manufacturing and scale-up, and complex synthetic processing. Siegfried's product portfolio serves various therapeutic areas such as anesthetics, analgesics, and decongestants, among others. The company's substances are available in a variety of formulations, including capsules, injectables, and lozenges, among others. The company operates through manufacturing sites in Switzerland, the US, Malta, China, Germany, France, and Spain. Siegfried is headquartered in Zofingen, Aargau, Switzerland.
Headquarters
Switzerland
Address
Untere Bruhlstrasse 4, Zofingen, Aargau, 4800
Website
www.siegfried.ch
Telephone
41 627 461111
No of Employees
3,891
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SFZN (SWF)
Revenue (2024)
$1.6B
2.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
5.4%
(2024 vs 2023)
Market Cap*
$4.1B
Net Profit Margin (2024)
XYZ
2.8%
(2024 vs 2023)
* As of and is in US$
Siegfried Holding AG premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Drug Substance: | Contract Development and Manufacturing |
| Active Pharmaceutical Ingredients (API) | Exclusive Synthesis |
| Intermediates | Supply Chain Management |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Corporate Changes/Expansions | In June, the company opened its new large-scale production facility for API manufacturing in Minden, Germany. |
| 2026 | Acquisitions/Mergers/Takeovers | In May, the company acquired Noramco, Extractas Biosciences, and Purisys of the Noramco Group from affiliates of funds advised by SK Capital Partners, LP, a private investment firm. |
| 2026 | Regulatory Approval | In April, the company secured antitrust clearance for the acquisition of three drug substance sites in the US and Australia from an affiliate of SK Capital Partners. |
Competitor Comparison
| Key Parameters | Siegfried Holding AG | Lonza Group Ltd | Perrigo Co Plc | Bachem Holding AG | Corden Pharma Switzerland LLC |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Ireland | Switzerland | Switzerland |
| City | Zofingen | Basel | Dublin | Bubendorf | Liestal |
| State/Province | Aargau | Basel-Stadt | Dublin | - | Basel-Landschaft |
| No. of Employees | 3,891 | 16,866 | 8,100 | 2,511 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Martin Schmid | Vice Chairman | Executive Board | 2016 | 57 |
| Marcel Imwinkelried | Chief Operating Officer - Drug Products and Interim; Chief Executive Officer | Senior Management | 2024 | 59 |
| Reto Suter | Chief Financial Officer | Senior Management | 2017 | 55 |
| Stefan Randl | Chief Scientific Officer | Senior Management | 2025 | 53 |
| Luca Dalla Torre | Chief Legal and Sustainability Officer | Senior Management | 2025 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer